RSV 6120/∆NS2/1030s
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for RSV 6120/∆NS2/1030s, covering 2023-08-03 to 2025-02-21. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age [Phase 1, Phase 2]